Nevro Corp.
US ˙ NYSE ˙ US64157F1030
DETTE SYMBOL ER IKKE LÆNGERE AKTIVT

SecurityNVRO / Nevro Corp.
InstitutionHealthCor Management, L.P.
Latest Disclosed Ownership156,046 shares
Ownership 0.50%
HealthCor Management, L.P. ownership in NVRO / Nevro Corp.

2021-02-12 - HealthCor Management, L.P. has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 156,046 shares of Nevro Corp. (US:NVRO). This represents 0.5 percent ownership of the company. In their previous filing dated 2020-03-27 , HealthCor Management, L.P. had reported owning 1,747,620 shares, indicating a decrease of -91.07 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2021-02-12 2021-02-12 13G/A 1,747,620 156,046 -91.07 0.50 -90.91
2020-03-27 2020-03-27 13G 1,747,620 5.50

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2023-02-14 2022-12-31 13F NEVRO COM 64157F103 0 -67,600 -100.00 0 -100.00
2022-11-14 2022-09-30 13F NEVRO COM 64157F103 67,600 67,600 3,150 0.3940
2022-05-16 2022-03-31 13F NEVRO COM 64157F103 0 -409,230 -100.00 0 -100.00
2022-02-14 2021-12-31 13F NEVRO COM 64157F103 409,230 -120,000 -22.67 33,176 -46.14 1.8053
2021-11-15 2021-09-30 13F NEVRO COM 64157F103 529,230 152,900 40.63 61,592 -1.28 2.6577
2021-08-16 2021-06-30 13F NEVRO COM 64157F103 376,330 376,330 62,392 2.4939
2021-05-17 2021-03-31 13F NEVRO COM 64157F103 0 -156,046 -100.00 0 -100.00
2021-02-16 2020-12-31 13F NEVRO COM 64157F103 156,046 -574,931 -78.65 27,012 -73.47 1.0417
2020-11-16 2020-09-30 13F NEVRO COM 64157F103 730,977 -323,126 -30.65 101,825 -19.14 4.0752
2020-08-14 2020-06-30 13F NEVRO COM 64157F103 1,054,103 -698,517 -39.86 125,934 -28.13 5.2760
2020-05-15 2020-03-31 13F NEVRO COM 64157F103 1,752,620 582,540 49.79 175,227 27.41 7.4892
2020-02-14 2019-12-31 13F NEVRO COM 64157F103 1,170,080 216,260 22.67 137,531 67.72 4.9064
2019-11-14 2019-09-30 13F NEVRO COM 64157F103 953,820 -273,910 -22.31 82,000 3.02 3.0995
2019-08-14 2019-06-30 13F NEVRO COM 64157F103 1,227,730 970,740 377.73 79,594 395.48 3.0882
2019-05-15 2019-03-31 13F NEVRO COM 64157F103 256,990 101,580 65.36 16,064 165.78 0.6490
2019-02-14 2018-12-31 13F/A-1 NEVRO COM 64157F103 155,410 155,410 -39.53 6,044 -62.38 0.1889
2016-08-15 2016-06-30 13F NEVRO COM 64157F103 0 -430,877 -100.00 0 -100.00
2016-05-16 2016-03-31 13F NEVRO COM 64157F103 430,877 430,877 24,241 1.3734
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.